Licensing by Inflammatory Cytokines Abolishes Heterogeneity of Immunosuppressive Function of Mesenchymal Stem Cell Population - PubMed (original) (raw)

. 2015 Sep 15;24(18):2171-80.

doi: 10.1089/scd.2014.0581. Epub 2015 Jul 8.

Affiliations

• PMID: 26153898
• DOI: 10.1089/scd.2014.0581

Licensing by Inflammatory Cytokines Abolishes Heterogeneity of Immunosuppressive Function of Mesenchymal Stem Cell Population

Enikő Szabó et al. Stem Cells Dev. 2015.

Abstract

When mesenchymal stem cells (MSCs) are used for therapy of immunological pathologies, they get into an inflammatory environment, altering the effectiveness of the treatment. To establish the impact of environmental inflammatory factors on MSCs' immunofunction in the mirror of intrinsic heterogeneity of mouse MSC population, individual MSC clones were generated and characterized. Adipogenic but not osteogenic differentiation and pro-angiogenic activity of five independent MSC cell lines were similar. Regarding osteogenic differentiation, clones MSC3 and MSC6 exhibited poorer capacity than MSC2, MSC4, and MSC5. To study the immunosuppressive heterogeneity, in vitro and in vivo experiments have been carried out using T-cell proliferation assay and delayed-type hypersensitivity (DTH) response, respectively. A remarkable difference was found between the clones in their ability to inhibit T-cell proliferation in the following order: MSC2≥MSC5>MSC4>MSC3 >> MSC6. Nevertheless, the differences between the immunosuppressive activities of the individual clones disappeared on pretreatment of the cells with pro-inflammatory cytokines, a procedure called licensing. Stimulation of all clones with IFN-γ and TNF-α resulted in elevation of their inhibitory capability to a similar level. Nitric oxide (NO) and prostaglandin E2 (PGE2) were identified as major mediators of immunofunction of the MSC clones. The earlier findings were also supported by in vivo results. Without licensing, MSC2 inhibited DTH response, while MSC6 did not affect DTH response. In contrast, prestimulation of MSC6 with inflammatory cytokines resulted in strong suppression by this clone as well. Here, we have showed that MSC population is functionally heterogeneous in terms of immunosuppressive function; however, this variability is largely reduced under pro-inflammatory conditions.

PubMed Disclaimer

Similar articles

• Heterogeneity of the biological properties and gene expression profiles of murine bone marrow stromal cells.
  Lei J, Hui D, Huang W, Liao Y, Yang L, Liu L, Zhang Q, Qi G, Song W, Zhang Y, Xiang AP, Zhou Q. Lei J, et al. Int J Biochem Cell Biol. 2013 Nov;45(11):2431-43. doi: 10.1016/j.biocel.2013.07.015. Epub 2013 Jul 30. Int J Biochem Cell Biol. 2013. PMID: 23911306
• Activated T-cells and pro-inflammatory cytokines differentially regulate prostaglandin E2 secretion by mesenchymal stem cells.
  Hegyi B, Kudlik G, Monostori E, Uher F. Hegyi B, et al. Biochem Biophys Res Commun. 2012 Mar 9;419(2):215-20. doi: 10.1016/j.bbrc.2012.01.150. Epub 2012 Feb 7. Biochem Biophys Res Commun. 2012. PMID: 22333568
• Immunomodulatory properties of colonic mesenchymal stem cells.
  Hu J, Zhang X, Zhou L, Zhang Y. Hu J, et al. Immunol Lett. 2013 Nov-Dec;156(1-2):23-9. doi: 10.1016/j.imlet.2013.09.006. Epub 2013 Sep 20. Immunol Lett. 2013. PMID: 24060593
• Mesenchymal stem cells and adaptive immune responses.
  Cao W, Cao K, Cao J, Wang Y, Shi Y. Cao W, et al. Immunol Lett. 2015 Dec;168(2):147-53. doi: 10.1016/j.imlet.2015.06.003. Epub 2015 Jun 12. Immunol Lett. 2015. PMID: 26073566 Review.
• Interactions between MSCs and immune cells: implications for bone healing.
  Kovach TK, Dighe AS, Lobo PI, Cui Q. Kovach TK, et al. J Immunol Res. 2015;2015:752510. doi: 10.1155/2015/752510. Epub 2015 Apr 27. J Immunol Res. 2015. PMID: 26000315 Free PMC article. Review.

Cited by

• Klotho and Mesenchymal Stem Cells: A Review on Cell and Gene Therapy for Chronic Kidney Disease and Acute Kidney Disease.
  Franco ML, Beyerstedt S, Rangel ÉB. Franco ML, et al. Pharmaceutics. 2021 Dec 21;14(1):11. doi: 10.3390/pharmaceutics14010011. Pharmaceutics. 2021. PMID: 35056905 Free PMC article. Review.
• Advances in mesenchymal stromal cell therapy for acute lung injury/acute respiratory distress syndrome.
  Liu C, Xiao K, Xie L. Liu C, et al. Front Cell Dev Biol. 2022 Aug 10;10:951764. doi: 10.3389/fcell.2022.951764. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36036014 Free PMC article. Review.
• Pro-Inflammatory Cytokine Priming and Purification Method Modulate the Impact of Exosomes Derived from Equine Bone Marrow Mesenchymal Stromal Cells on Equine Articular Chondrocytes.
  Jammes M, Cassé F, Velot E, Bianchi A, Audigié F, Contentin R, Galéra P. Jammes M, et al. Int J Mol Sci. 2023 Sep 16;24(18):14169. doi: 10.3390/ijms241814169. Int J Mol Sci. 2023. PMID: 37762473 Free PMC article.
• Novel therapies using cell sheets engineered from allogeneic mesenchymal stem/stromal cells.
  Kondo M, Kameishi S, Grainger DW, Okano T. Kondo M, et al. Emerg Top Life Sci. 2020 Dec 17;4(6):677-689. doi: 10.1042/ETLS20200151. Emerg Top Life Sci. 2020. PMID: 33231260 Free PMC article. Review.
• Interferon-Gamma Primed Human Clonal Mesenchymal Stromal Cell Sheets Exhibit Enhanced Immunosuppressive Function.
  Dunn CM, Kameishi S, Cho YK, Song SU, Grainger DW, Okano T. Dunn CM, et al. Cells. 2022 Nov 23;11(23):3738. doi: 10.3390/cells11233738. Cells. 2022. PMID: 36497001 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon